The global type I diabetes mellitus treatment market is expected to experience significant growth during the forecast period, driven by factors such as the availability of insulin for treatment and the rising prevalence of the disease. Type I diabetes mellitus is a chronic illness characterized by the body’s inability to produce insulin, resulting in various symptoms such as excessive urination, hunger, thirst, weight loss, and fatigue.
Get a Sample Copy of the Market Research Report (Use Corporate Mail Id for Quick Response) https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=58923
According to recent statistics, over 1.25 million children and adults were diagnosed with type I diabetes in the United States alone in 2017. The World Health Organization (WHO) predicts a higher prevalence of type I diabetes mellitus in countries such as Sardinia, New Zealand, Sweden, Finland, Norway, the U.K., Portugal, and Canada. This growing patient pool is expected to drive the global type I diabetes mellitus treatment market.
The market is also witnessing a surge in research and development activities, leading to a growing pipeline of exogenous insulin products. Government funding for research on treatment modes for type I diabetes mellitus further supports market growth. However, the market faces challenges such as patent expiries and price competition among market players due to the increased usage of biologics.
North America currently holds the largest share of the global type I diabetes mellitus treatment market, attributed to its well-established healthcare infrastructure and high prevalence of the disease. Europe is expected to be the second leading market, although sluggish economic growth may hinder its growth in the coming years. The Asia Pacific region is projected to witness significant growth, driven by government initiatives to enhance healthcare facilities and a rising patient population.
Key players in the global type I diabetes mellitus treatment market include Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Merck & Co., Inc., Novartis International AG, AstraZeneca plc, Biocon Limited, and others. These players are actively engaged in partnerships and collaborations to expand their global footprint and meet the growing demand for insulin analogs.
The market is segmented based on insulin analogs, including long-acting insulin analogs, premix analogs, rapid-acting insulin analogs, and others. Distribution channels for type I diabetes mellitus treatment include hospital pharmacies, retail pharmacies and drugstores, online sales, and others.
For further information, please contact:
Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453